AUTHOR=Lang Hui , Peng Cheng , Wu Kongyuan , Chen Xiwen , Jiang Xin , He Li , Chen Ning 

TITLE=Efficacy and safety of onabotulinumtoxinA in the treatment of medication overuse headache: a systematic review

JOURNAL=Frontiers in Neurology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1453183

DOI=10.3389/fneur.2024.1453183

ISSN=1664-2295

ABSTRACT=<sec id="sec1"><title>Purpose</title><p>Medication overuse headache (MOH) is a chronic headache caused by regular overuse of medications. OnabotulinumtoxinA (BoNTA) is used for preventive treatment of MOH. However, its efficacy and safety remain controversial.</p></sec><sec id="sec2"><title>Methods</title><p>Seven online databases (Cochrane Library, Embase, Medline, PubMed, China National Knowledge Infrastructure, Wanfang data, and Chinese BioMedical Literature Database) were searched for relevant articles published between January 2002 and March 2024. We included randomized controlled trials (RCTs) and cohort studies on the treatment of MOH using BoNTA versus a placebo or other active treatments.</p></sec><sec id="sec3"><title>Results</title><p>We retrieved 487 articles in the database search. Of these, four eligible RCTs were identified after detailed screening. A total of 1,259 patients with MOH (622 patients treated with BoNTA, 607 with placebo, and 30 with topiramate) were included in the four RCTs. We found that BoNTA significantly reduced headache frequency compared with placebo (mean difference, 1.89; 95% confidence interval (CI), 1.11–2.67; <italic>I</italic><sup>2</sup> = 0%; <italic>p</italic> &lt; 0.001). There was no significant difference between BoNTA and the placebo in terms of secondary outcomes, which included reductions in acute medication intake (MD, 1.30; 95% CI, −1.18–3.78; <italic>I</italic><sup>2</sup> = 0%; <italic>p</italic> = 0.30), Migraine Disability Assessment questionnaire scores (MIDAS, MD, −4.04; 95% CI, −29.36–21.28; <italic>I</italic><sup>2</sup> = 0%; <italic>p</italic> = 0.75), and Headache Impact Test scores (HIT-6, MD, 0.03; 95% CI, −1.77–1.83; <italic>I</italic><sup>2</sup> = 0%; <italic>p</italic> = 0.97). BoNTA was more likely to cause adverse events (OR, 1.87; 95% CI, 1.45–2.42; <italic>I</italic><sup>2</sup> = 0%; <italic>p</italic> &lt; 0.001) than placebo.</p></sec><sec id="sec4"><title>Conclusion</title><p>The results of this study show that BoNTA reduces headache frequency and is effective for the treatment of MOH.</p></sec><sec id="sec5"><title>Systematic review registration</title><p><ext-link xlink:href="https://www.crd.york.ac.uk/prospero/" ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/prospero/</ext-link>, identifier CRD42022315845.</p></sec>